 | V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate... 6 KB (421 words) - 03:40, 24 November 2023 |
Soberana 02 (a conjugate vaccine). Bimervax was approved for use as a booster vaccine in the European Union in March 2023. The V451 vaccine was in clinical trials... 192 KB (21,930 words) - 19:29, 15 April 2024 |
 | BioNTech (category COVID-19 vaccine producers) CureVac Moderna COVID-19 vaccine Novavax COVID-19 vaccine Oxford–AstraZeneca COVID-19 vaccine Sputnik V COVID-19 vaccine V451 vaccine "BioNTech 2023 Annual... 40 KB (3,633 words) - 02:16, 24 March 2024 |
| from the original on 11 October 2020. Retrieved 4 August 2020. "UQ-CSL V451 Vaccine". precisionvaccinations.com. Retrieved 11 December 2020. "Dose Ranging... 98 KB (20,593 words) - 02:58, 8 March 2024 |
 | CSL Limited (section Vaccines) supply the University of Queensland vaccine (V451) and to manufacture (with AstraZeneca) the Oxford University vaccine (AZD1222), which would yield nearly... 30 KB (2,888 words) - 09:54, 3 March 2024 |
have experienced a contraction from 2019 figures. On 11 December, the V451 vaccine being developed at the University of Queensland was abandoned after trials... 123 KB (11,748 words) - 23:27, 11 March 2024 |
 | Adenoviridae (section Vaccines) UQ-CSL V451. The Gam-COVID-Vac (aka Sputnik-V) product is innovative because an Ad26 based vaccine is used on the first day and an Ad5 vaccine is used... 49 KB (5,557 words) - 01:25, 8 March 2024 |
Molecular clamp (category Subunit vaccines) UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials". Reuters. 2020-12-10. Retrieved 2020-12-11. "Australia ends local COVID vaccine trials... 6 KB (634 words) - 00:04, 10 November 2023 |
five days, but may range from two to fourteen days. There is no known vaccine or specific antiviral treatment. Primary treatment is symptomatic and supportive... 181 KB (23,901 words) - 14:23, 6 January 2024 |